NKCx Histopathological outcome* within 12 months after cervix cytology in 2021
121 Uppsala

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 38 0.4% 26 0.3% 6 0.1% . . . . . . 9185 99.2% 9255 100.0%
ASCUS 41 5.7% 247 34.4% 130 18.1% 5 0.7% 3 0.4% 1 0.1% 290 40.4% 717 100.0%
LSIL 24 5.7% 158 37.3% 130 30.7% . . . . . . 112 26.4% 424 100.0%
Atypical glandular cells/AGC . . 1 20.0% . . 4 80.0% . . . . . . 5 100.0%
ASC-H 2 2.8% 9 12.5% 54 75.0% 3 4.2% . . . . 4 5.6% 72 100.0%
HSIL 1 0.9% 13 11.9% 84 77.1% 4 3.7% 6 5.5% . . 1 0.9% 109 100.0%
Suspected Adenocarcinom . . 1 25.0% . . 2 50.0% 1 25.0% . . . . 4 100.0%
Squamous cell cancer . . . . . . . . 2 66.7% . . 1 33.3% 3 100.0%
Totalt 106 1.0% 455 4.3% 404 3.8% 18 0.2% 12 0.1% 1 0.0% 9593 90.6% 10589 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the category
Cancer:
M80009, M80703, M81403